Werbung
Werbung
NTLA
Intellia Therapeutics, Inc
10.52
USDGesponsert
+0.40
+3.99%
08. Jan., 16:00 UTC -5
Geschlossen
Vor-Markt
10.62
+0.10
+0.95%
NTLA Ergebnisberichte
Positives Überraschungsverhältnis
NTLA übertreffen die 21 der letzten 39Schätzungen.
54%
Nächster Bericht
Datum des nächsten Berichts
25. Feb. 2026
Estimate for Q4 25 (Revenue/ EPS)
$13.04M
/-$0.97
Implizierte Änderung von Q3 25 (Revenue/ EPS)
-5.36%
/+5.43%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
+1.31%
/-23.62%
Intellia Therapeutics, Inc earnings per share and revenue
On 06. Nov. 2025, NTLA reported earnings of -0.92 USD per share (EPS) for Q3 25, beating the estimate of -1.02 USD, resulting in a 9.97% surprise. Revenue reached 13.78 million, compared to an expected 15.49 million, with a -11.02% difference. The market reacted with a -22.73% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 23 analysts forecast an EPS of -0.97 USD, with revenue projected to reach 13.04 million USD, implying an increase of 5.43% EPS, and decrease of -5.36% in Revenue from the last quarter.
FAQ
What were Intellia Therapeutics, Inc's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Intellia Therapeutics, Inc reported EPS of -$0.92, beating estimates by 9.97%, and revenue of $13.78M, -11.02% below expectations.
How did the market react to Intellia Therapeutics, Inc's Q3 2025 earnings?
The stock price moved down -22.73%, changed from $12.32 before the earnings release to $9.52 the day after.
When is Intellia Therapeutics, Inc expected to report next?
The next earning report is scheduled for 25. Feb. 2026.
What are the forecasts for Intellia Therapeutics, Inc's next earnings report?
Based on 23
analysts, Intellia Therapeutics, Inc is expected to report EPS of -$0.97 and revenue of $13.04M for Q4 2025.
Which companies are reporting earnings today?
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung